GBI Biomanufacturing Expands Its Drug Product Capabilities
GBI Biomanufacturing (GBI), a prominent player in the contract development and manufacturing organization (CDMO) sector, has recently enhanced its capabilities by introducing automated sterile fill and finish services for drug products. This strategic move aims to better support clients navigating from clinical trials to commercial launches in the pharmaceutical and biotech industries.
Commitment to Quality and Flexibility
With a strong emphasis on providing advanced solutions, GBI's automated aseptic fill-finish capabilities empower them to fulfil diverse client needs. The company understands the importance of precision and efficiency, particularly for clients working on smaller clinical batches or formulations requiring special handling. Their manual aseptic vial filling process remains flexible and adaptable, while their automated aseptic liquid filling enhances production efficiency and batch consistency.
Innovative Solutions for Modern Needs
The integration of automated systems allows GBI to maintain high throughput while minimizing the risk of contamination in drug product manufacturing. This capability is essential not only for clinical trials but also for commercial-scale projects. The combination of automated and manual filling methods provided by GBI creates a comprehensive system that can cater to a wide range of pharmaceutical applications.
CEO's Insight on Expanded Services
Karl Pinto, CEO of GBI, expressed enthusiasm about the new offerings: "Adding automated aseptic fill-finish capabilities to our service offerings strengthens our ability to meet the diverse requirements of our clients, from start-up biotech to established pharmaceutical companies." GBI's facility is equipped with the latest technology and staffed by a team of experts dedicated to delivering high-quality and regulatory-compliant drug products.
Supporting Various Drug Classes
GBI's new automated filling technology is capable of supporting vials, syringes, and cartridges across multiple drug classes, including biologics, vaccines, bioconjugates, and complex large molecules. This versatility underlines GBI's mission to serve as an end-to-end solution provider, simplifying the supply chains of its clients and facilitating quicker project turnaround times.
Strategic Advantages for Clients
The addition of automated aseptic fill-finish capabilities aligns with GBI's broader objective to deliver end-to-end development and cGMP manufacturing services. By consolidating the manufacturing process of both drug substances and drug products in one location, GBI is helping clients achieve faster timelines and ensuring compliance with regulatory requirements.
This integrated approach not only increases efficiency but also streamlines operations for clients who can now source DS and DP from a single site, significantly reducing the complexities associated with coordinating multiple suppliers.
About GBI Biomanufacturing
GBI is recognized as a leading CDMO dedicated to providing top-notch services to the global pharmaceutical and biotech sectors. With expertise ranging from process development and analytical services to drug substance manufacturing and sterile fill-finish operations, GBI plays a crucial role in the development and commercialization of life-saving therapies around the world.
Frequently Asked Questions
What services does GBI Biomanufacturing provide?
GBI offers a range of services including process development, analytical services, drug substance manufacturing, and sterile fill-finish operations.
How does the new automated aseptic fill-finish system work?
This system allows for high-throughput production while reducing contamination risks through minimal human intervention.
What drug classes can GBI's new filler support?
The filler can accommodate various drug classes including biologics, vaccines, bioconjugates, and complex large molecules.
Who is the CEO of GBI Biomanufacturing?
Karl Pinto is the current CEO of GBI Biomanufacturing.
Where is GBI Biomanufacturing located?
GBI's facility is located in Florida, USA, where it provides all its services from one site.
